查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1608217

肠漏症候群治疗市场：按治疗类型、给药途径、分销管道和最终用户划分 - 全球预测 2025-2030

Lennox-Gastaut Syndrome Treatment Market by Therapy Type (Non-Surgical Treatment, Surgery), Route of Administration (Oral, Parenteral), Distribution Channel, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

肠漏症候群治疗市场2023年估值为6.4329亿美元，预计到2024年将达到6.7063亿美元，复合年增长率为5.28%，到2030年将达到9.2238亿美元。

肠漏症候群(LGS) 是一种罕见且严重的癫痫类型，通常始于儿童早期，以多种癫痫类型和认知功能障碍为特征。 LGS 治疗的市场范围包括诊断、癫痫发作管理和改善患者生活品质。目前，考虑到 LGS 的严重程度和抗治疗性，市场受到高度未满足的医疗需求的推动。用途包括抗癫痫药物、饮食疗法和手术干预，重点是减少癫痫发作频率和严重程度。最终使用领域主要包括儿科神经科、专科诊所、医院和居家照护环境。

主要市场统计
基准年[2023] 64329万美元
预测年份 [2024] 67063万美元
预测年份 [2030] 92238万美元
复合年增长率（%） 5.28%

LGS 治疗市场的成长很大程度上取决于意识和诊断能力的提高，从而实现早期检测。此外，正在进行的临床试验和对大麻二酚（CBD）製剂等新药物机制的研究为市场扩张提供了潜在的机会。研究还包括利用基因研究和个人化医疗的进步来开发更有针对性的治疗方法。然而，市场面临治疗成本高、现有药物副作用以及新药认证复杂的监管环境等限制，为成长带来挑战。此外，我们对 LGS 潜在病理生理学的了解有限，为突破性创新创造了充满挑战的环境。

创新和研究的最佳潜在领域包括寻找具有改善功效和安全性的新型药物製剂、增强神经刺激设备等非药物疗法，例子包括基因治疗的进展。鼓励合作研究工作以及与学术机构的伙伴关係也可以为开创性治疗铺平道路。市场的动态和利基性质要求同时关注治疗方法开发和综合护理模式。产业公司应投资于长期研发和策略合作伙伴关係，以创建创新的解决方案，解决与 LGS 相关的癫痫和认知障碍。

市场动态：快速发展的肠漏症候群治疗市场的关键市场洞察

肠漏症候群治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 具有 LGS 危险因子并需要治疗的人口不断增加
    • 各国政府和国际组织对 LGS 的认可度不断提高
    • 孤儿药认定增加
  • 市场限制因素
    • LGS 诊断的限制和治疗费用高
  • 市场机会
    • LGS 处理植物化学简介
    • LGS治疗的技术进步
  • 市场挑战
    • 与现有治疗相关的副作用

波特的五力：驾驭肠漏症候群治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肠漏症候群治疗市场的外部影响

外部宏观环境因素在塑造肠漏症候群治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肠漏症候群治疗市场的竞争格局

对肠漏症候群治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肠漏症候群治疗市场供应商的绩效评估

FPNV 定位矩阵是评估肠漏症候群治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为肠漏症候群治疗市场的成功指明道路

对于希望加强在全球市场的影响力的公司来说，对肠漏症候群治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 具有 LGS 危险因子并需要治疗的人口不断增加
      • 各国政府和国际组织对 LGS 的认识不断提高
      • 孤儿药认定增加
    • 抑制因素
      • LGS 诊断的限制和治疗费用高
    • 机会
      • LGS 处理植物化学物质简介
      • LGS治疗的技术进步
    • 任务
      • 与现有治疗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肠漏症候群治疗市场（依治疗类型）

  • 非手术治疗
    • 静脉注射免疫球蛋白治疗
    • 生酮饮食产品
  • 外科手术

第七章肠漏症候群治疗市场：依给药途径

  • 口服
  • 胃肠外的

第八章肠漏症候群治疗市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第 9 章肠漏症候群治疗市场：依最终使用者分类

  • 居家护理
  • 医院
  • 专科诊所

第10章美洲肠漏症候群治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太肠漏症候群治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲肠漏症候群治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Amneal Pharmaceuticals Inc.
  • Aquestive Therapeutics Inc.
  • Bausch Health Companies Inc.
  • Cision Ltd.
  • Eisai Co. Ltd.
  • GlaxoSmithKline PLC
  • GW Pharmaceuticals PLC
  • H. Lundbeck A/S
  • Johnson and Johnson
  • Lupin Ltd.
  • Marinus Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Supernus Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Upsher Smith Laboratories LLC
  • Viatris Inc.
Product Code: MRR-742BD518076B

The Lennox-Gastaut Syndrome Treatment Market was valued at USD 643.29 million in 2023, expected to reach USD 670.63 million in 2024, and is projected to grow at a CAGR of 5.28%, to USD 922.38 million by 2030.

Lennox-Gastaut Syndrome (LGS) is a rare and severe form of epilepsy that typically manifests in early childhood and is characterized by multiple types of seizures and cognitive impairment. The scope of the market for LGS treatment includes diagnosing, managing seizures, and improving patients' quality of life. Currently, necessity in the market is driven by the high unmet medical need given the severity and resistance of LGS to treatments. Application includes antiepileptic drugs, dietary therapies, and surgical interventions, focusing on reducing seizure frequency and severity. The end-use scope primarily covers pediatric neurology departments, specialty clinics, hospitals, and home care settings.

KEY MARKET STATISTICS
Base Year [2023] USD 643.29 million
Estimated Year [2024] USD 670.63 million
Forecast Year [2030] USD 922.38 million
CAGR (%) 5.28%

The growth of the LGS treatment market is significantly influenced by increased awareness and diagnostic capabilities, leading to early detection. Additionally, ongoing clinical trials and research into new drug mechanisms, such as Cannabidiol (CBD) formulations, have presented potential opportunities for market expansion. Recommendations include leveraging advances in genetic research and personalized medicine to develop more targeted therapies. However, the market faces limitations such as high treatment costs, side effects of existing medications, and a complex regulatory landscape for new drug approvals, which challenge growth. The market is further constrained by limited understanding of LGS's underlying pathophysiology, resulting in a challenging environment for breakthrough innovations.

The best possible areas for innovation and research include exploring novel pharmacological agents with improved efficacy and safety profiles, enhancing non-pharmacological therapies like neurostimulation devices, and pushing advancements in gene therapy. Encouraging collaborative research initiatives and partnerships with academic institutions can also pave the way for pioneering treatments. The nature of the market is dynamic and niche, necessitating focus on both therapy development and comprehensive care models. Players in the industry should invest in long-term R&D and strategic alliances to create innovative solutions that address both the seizures and cognitive impairments associated with LGS.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lennox-Gastaut Syndrome Treatment Market

The Lennox-Gastaut Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising population with risk factors for LGS and need for treatment
    • Growing awareness of LGS by governments and global organizations
    • Rise in orphan drug designation
  • Market Restraints
    • Limitations in diagnosing LGS and high cost of treatment
  • Market Opportunities
    • Introduction of phytochemicals for LGS treatment
    • Technological advancements in the treatment of LGS
  • Market Challenges
    • Side effects associated with available treatment

Porter's Five Forces: A Strategic Tool for Navigating the Lennox-Gastaut Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lennox-Gastaut Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lennox-Gastaut Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lennox-Gastaut Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lennox-Gastaut Syndrome Treatment Market

A detailed market share analysis in the Lennox-Gastaut Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lennox-Gastaut Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lennox-Gastaut Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lennox-Gastaut Syndrome Treatment Market

A strategic analysis of the Lennox-Gastaut Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lennox-Gastaut Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Bausch Health Companies Inc., Cision Ltd., Eisai Co. Ltd., GlaxoSmithKline PLC, GW Pharmaceuticals PLC, H. Lundbeck A/S, Johnson and Johnson, Lupin Ltd., Marinus Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, Upsher Smith Laboratories LLC, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Lennox-Gastaut Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Non-Surgical Treatment and Surgery. The Non-Surgical Treatment is further studied across Intravenous Immunoglobulin Therapy and Ketogenic Diet Products.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising population with risk factors for LGS and need for treatment
      • 5.1.1.2. Growing awareness of LGS by governments and global organizations
      • 5.1.1.3. Rise in orphan drug designation
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations in diagnosing LGS and high cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of phytochemicals for LGS treatment
      • 5.1.3.2. Technological advancements in the treatment of LGS
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with available treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lennox-Gastaut Syndrome Treatment Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Non-Surgical Treatment
    • 6.2.1. Intravenous Immunoglobulin Therapy
    • 6.2.2. Ketogenic Diet Products
  • 6.3. Surgery

7. Lennox-Gastaut Syndrome Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral

8. Lennox-Gastaut Syndrome Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Lennox-Gastaut Syndrome Treatment Market, by End Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Lennox-Gastaut Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Lennox-Gastaut Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Lennox-Gastaut Syndrome Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amneal Pharmaceuticals Inc.
  • 3. Aquestive Therapeutics Inc.
  • 4. Bausch Health Companies Inc.
  • 5. Cision Ltd.
  • 6. Eisai Co. Ltd.
  • 7. GlaxoSmithKline PLC
  • 8. GW Pharmaceuticals PLC
  • 9. H. Lundbeck A/S
  • 10. Johnson and Johnson
  • 11. Lupin Ltd.
  • 12. Marinus Pharmaceuticals Inc.
  • 13. Pfizer Inc.
  • 14. Sanofi SA
  • 15. Sun Pharmaceutical Industries Ltd
  • 16. Supernus Pharmaceuticals Inc.
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. UCB SA
  • 19. Upsher Smith Laboratories LLC
  • 20. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. LENNOX-GASTAUT SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. LENNOX-GASTAUT SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LENNOX-GASTAUT SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY KETOGENIC DIET PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM LENNOX-GASTAUT SYNDROME TREATMENT MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 233. LENNOX-GASTAUT SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. LENNOX-GASTAUT SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023